Laekna, Inc.

Laekna, Inc. (来凯医药) is a science-driven biotechnology company listed on the Hong Kong Stock Exchange under the stock code 2105.HK. According to its official website, the company focuses on patient needs in major disease areas such as metabolic diseases, oncology, and liver fibrosis, and has built a pipeline of over 20 internally discovered innovative drug candidates with proprietary intellectual property rights. Its oncology candidate LAE002 (afuresertib, an AKT inhibitor) completed a Phase III clinical trial for breast cancer (AFFIRM-205) that met its primary endpoint, and an NDA was submitted to the CDE in August 2026. Laekna has also entered an exclusive licensing agreement with Qilu Pharma for this therapeutic in China. The company is led by founder Dr. LU Chris Xiangyang, Chairman, Executive Director and CEO.

Laekna, Inc. is a science-driven biotechnology company. Dr. LU Chris Xiangyang is the founder of the Group and was appointed as a Director in July 2016 and re-designated as an executive Director in May 2022. He is responsible for overseeing the overall business strategy, R&D activities, business planning and operational management, and has over 20 years of drug discovery and development experience in the biotechnology and pharmaceutical industry. The company states that patient needs in major disease areas—such as metabolic diseases, oncology, and liver fibrosis—remain the driving force behind its mission, and that it has built a pipeline of over 20 internally discovered innovative drug candidates with proprietary intellectual property rights. In oncology, the Phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) for breast cancer (AFFIRM-205) was completed and successfully met its primary endpoint; an NDA was submitted to the CDE in August 2026, which the company describes as its pivotal transition from clinical development to commercialization. Laekna has entered into an exclusive licensing agreement with Qilu Pharma to further accelerate the delivery of this novel therapeutic to patients across China.

A science-driven biotechnology company committed to bringing novel therapeutics to patients around the world.

• LAE002 (afuresertib)

  An AKT inhibitor; its Phase III clinical trial for breast cancer (AFFIRM-205) was completed and successfully met its primary endpoint.

• LAE118

  An internally discovered drug candidate mentioned on the company's About page.

1. 1Laeknalaekna.com
2. 2About Laekna - Company - Laeknalaekna.com
3. 3Board of Directors - Corporate Governance - Investors - Laeknalaekna.com
4. 4Laekna, Inc. (China)wikidata.org